Amgen Inc. (AMGN)

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen is the latest drugmaker to sell certain drugs directly to consumers amid pressure from President Donald Trump. Meanwhile, Dr. Oz talks GLP-1s for obesity.

AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.

Amgen (AMGN) reached $294.12 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to U.S. political pressure to lower drug prices.

Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price  THOUSAND OAKS, Calif. , Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab).

Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price. Analyst forecasts suggest top-ten Dow Dogs could deliver average net gains of 20% by October 2026, with VZ among the safer high-yield picks. Most Dow Dogs remain overpriced relative to their dividends, but market pullbacks could create fair-value opportunities for income-focused investors.

Major market indexes such as the S&P 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant Amgen (AMGN 0.19%) started the year strong, but has not maintained that momentum.

Jim Cramer breaks down why he's keeping an eye on shares of Amgen.

The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only PCSK9 Inhibitor to Demonstrate Significant Reduction of Cardiovascular Events as Both Primary and Secondary Prevention THOUSAND OAKS, Calif. , Oct. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha® (evolocumab) significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke.

There are a million and one ways to put your money to work on Wall Street. It might surprise you to learn that investing in dividend growth stocks isn't just one of the easiest; it's also one of the most effective.